<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>ajedropolis.com &#187; European</title>
	<atom:link href="http://www.ajedropolis.com/tag/european/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.ajedropolis.com</link>
	<description>US Business &#38; Insurance</description>
	<lastBuildDate>Sat, 11 Feb 2012 18:14:52 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3</generator>
		<item>
		<title>General Protalix successful European GMP Audit</title>
		<link>http://www.ajedropolis.com/general-protalix-successful-european-gmp-audit/</link>
		<comments>http://www.ajedropolis.com/general-protalix-successful-european-gmp-audit/#comments</comments>
		<pubDate>Fri, 02 Dec 2011 09:02:28 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Regulatory Differences]]></category>
		<category><![CDATA[Audit]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[General]]></category>
		<category><![CDATA[Protalix]]></category>
		<category><![CDATA[Successful]]></category>

		<guid isPermaLink="false">http://www.ajedropolis.com/general-protalix-successful-european-gmp-audit/</guid>
		<description><![CDATA[General Protalix successful Europe GMP Audit &#8230; differences include, among others: risks associated with any failure by us to comply with the GMP in respect of any product candidates in any jurisdiction; risks associated with the review process of the FDA, foreign regulatory and other EMA other &#8230; Read more about Sacramento Bee BoE chart, [...]]]></description>
			<content:encoded><![CDATA[<p>General Protalix successful <strong> Europe GMP Audit </strong><br />
&#8230; differences include, among others: risks associated with any failure by us to comply with the GMP in respect of any product candidates in any jurisdiction; risks associated with the review process of the FDA, foreign regulatory and other EMA other &#8230;<br />
<i> Read more about <a rel="nofollow" href="http://www.sacbee.com/2011/11/30/4091865/protalix-announces-successful.html"> Sacramento Bee </a> <br /> <br/> </i><br />
BoE <strong> chart, you risk weights can not be trusted </strong><br />
In doing so, it also introduces new sources of changes in regulatory capital ratio: the difference in their own estimates banks&#8217; RWAs. Slight changes in the bank model can contribute to financial stability. Banks with different beliefs can react &#8230;<br />
<i> Read more <a rel = "nofollow" href = "http://ftalphaville.ft.com/blog/2011/12/01/776281/boe-charts-risk-weights-you-cant-trust/" > FT Alphaville (blog) </a> <br/> </i><br />
Pennichuck <strong> scenario would be very unusual, perhaps even unique </strong><br />
Another difference, sexual to outsiders but is important in the industry, that Pennichuck would still be regulated by the state Public Utilities Commission, which must approve the rate increase. Typically, private utilities &#8230;<br />
<i> Read more at <a rel = "nofollow" Telegraph </a> <br/> </i></p>
]]></content:encoded>
			<wfw:commentRss>http://www.ajedropolis.com/general-protalix-successful-european-gmp-audit/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

